Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;60(2):977-979.
doi: 10.1093/rheumatology/keaa653.

An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic

Rishi Gupta  1 , Muhammad Shipa  2 , Su-Ann Yeoh  2 , Pauline Buck  1 , Michael R Ehrenstein  1   2
Affiliations

An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic

Rishi Gupta et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Details of patients who wanted to revert to i.v. from s.c. administration
See this image and copyright information in PMC

References

    1. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007;21:789–804. - PubMed
    1. Lauper K, Mongin D, Iannone F. et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open 2018;4:e000809. - PMC - PubMed
    1. Genovese MC, Covarrubias A, Leon G. et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854–64. - PMC - PubMed
    1. Reggia R, Franceschini F, Tincani A, Cavazzana I. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety. J Rheumatol 2015;42:193–5. - PubMed
    1. Bolge SC, Eldridge HM, Lofland JH. et al. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence 2017;11:661–9. - PMC - PubMed